INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmunityBio, Inc. - IBRXPRNewsWire • 03/26/26
ImmunityBio Confirms Statistical Power in Pivotal Randomized BCG-Naïve NMIBC Trial to Detect Clinically Meaningful Differences Between ANKTIVA® Plus BCG Versus BCG Alone; Supplemental BLA Submission on Track for 2026Business Wire • 03/26/26
IBRX Stock Slides on FDA Warning Over Misleading Cancer Drug ClaimsZacks Investment Research • 03/25/26
Rosen Law Firm Encourages ImmunityBio, Inc. Investors to Inquire About Securities Class Action Investigation – IBRXBusiness Wire • 03/25/26
ImmunityBio Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their LossesNewsfile Corp • 03/24/26
Can Anktiva's Label Expansion Unlock the Next Growth Phase for IBRX?Zacks Investment Research • 03/23/26
ImmunityBio Announces Approval in Macau SAR, China for ANKTIVA® in BCG-Unresponsive NMIBC with CIS ± Papillary TumorsBusiness Wire • 03/20/26
ImmunityBio's Anktiva Could See More Upside: My Updated Thoughts On ExpansionSeeking Alpha • 03/17/26
Will Anktiva Continue to Drive ImmunityBio's Top-Line Growth in 2026?Zacks Investment Research • 03/17/26
ImmunityBio Announces NCCN® Clinical Practice Guidelines in Oncology Have Been Updated to Include ANKTIVA® Plus BCG for Patients With BCG-Unresponsive NMIBC With Papillary-Only DiseaseBusiness Wire • 03/17/26
IBRX and the BCG Shortage: A 2026 Catalyst Investors Are TrackingZacks Investment Research • 03/13/26
ImmunityBio Achieves Milestone with Large-Scale NK Cell Production and Cryopreservation from Over 60 Healthy and Cancer DonorsBusiness Wire • 03/13/26